Patients baseline characteristics. by Shivani Patel (4742748)

“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”

Overall survival. by Shivani Patel (4742748)

“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”

CHWs house visits. by Nicole Michelén Ströfer (19269154)

“…The performance of the malaria CHW network was evaluated using weekly data collected from CHWs and routinely collected surveillance data from the Ministry of Public Health (MoH). We assess performance of CHWs by analyzing key variables including (1) reporting compliance, (2) household visitation rates, (3) malaria rapid diagnostic tests performed, (4) malaria cases detected, and (5) time between symptom onset and malaria diagnosis. …”

Progression-free survival by treatment. by Shivani Patel (4742748)

“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”

Maintenance regimen and adverse event management. by Shivani Patel (4742748)

“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”

BCC-specific survival. by Shivani Patel (4742748)

“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”

Influence of Precursor Solution Composition on the Electrical Properties of Solution-Processed Indium Tin Oxide Thin Films by Jingwei Zhang (288128)

“…The results reveal that incorporating nitrate anion-based precursors and Sn (II)-based precursors in the solutions leads to the ITO film with a low resistivity of 3.5 × 10^–3 Ω cm. …”

Influence of Precursor Solution Composition on the Electrical Properties of Solution-Processed Indium Tin Oxide Thin Films by Jingwei Zhang (288128)

“…The results reveal that incorporating nitrate anion-based precursors and Sn (II)-based precursors in the solutions leads to the ITO film with a low resistivity of 3.5 × 10^–3 Ω cm. …”

Transgenic FAR expression significantly decreases fly survival and increases bacterial load 24-hours post-injection. by Sophia C. Parks (11624976)

Sequence analysis of continually RDV selected SARS-CoV-2_Engl2. by Agnieszka M. Szemiel (10196243)

“…Calculated from 988 mutations observed in minimum of 5 sequences. Position of mutation associated with decrease RDV sensitivity in SARS-CoV-2 is highlighted in red and sites identified in murine hepatitis virus (MHV) and Ebola virus (EBOV) are indicated in black. …”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…Current treatments, such as teriparatide, boost bone formation but also elevate resorption, limiting their long-term effectiveness. We discovered 3-butyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<i>d</i>]pyrimidin-4(3<i>H</i>)-one <b>(5cc)</b>, an orally active phosphodiesterase-1 (PDE1) inhibitor aimed at restoring this balance. …”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…Current treatments, such as teriparatide, boost bone formation but also elevate resorption, limiting their long-term effectiveness. We discovered 3-butyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<i>d</i>]pyrimidin-4(3<i>H</i>)-one <b>(5cc)</b>, an orally active phosphodiesterase-1 (PDE1) inhibitor aimed at restoring this balance. …”

Discovery of an Orally Active PDE1 Inhibitor for Disease-Modifying Treatment of Postmenopausal Osteoporosis via Dual Anabolic-Antiresorptive Mechanisms by Farman M. Abbasi (22318766)

“…Current treatments, such as teriparatide, boost bone formation but also elevate resorption, limiting their long-term effectiveness. We discovered 3-butyl-5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-<i>d</i>]pyrimidin-4(3<i>H</i>)-one <b>(5cc)</b>, an orally active phosphodiesterase-1 (PDE1) inhibitor aimed at restoring this balance. …”

Image_5_LUMAN/CREB3 Plays a Dual Role in Stress Responses as a Cofactor of the Glucocorticoid Receptor and a Regulator of Secretion.TIF by Jenna Penney (5791379)

Image_5_LUMAN/CREB3 Plays a Dual Role in Stress Responses as a Cofactor of the Glucocorticoid Receptor and a Regulator of Secretion.TIF by Jenna Penney (5791379)

Image_5_LUMAN/CREB3 Plays a Dual Role in Stress Responses as a Cofactor of the Glucocorticoid Receptor and a Regulator of Secretion.TIF by Jenna Penney (5791379)

Image_5_LUMAN/CREB3 Plays a Dual Role in Stress Responses as a Cofactor of the Glucocorticoid Receptor and a Regulator of Secretion.TIF by Jenna Penney (5791379)

Image_5_LUMAN/CREB3 Plays a Dual Role in Stress Responses as a Cofactor of the Glucocorticoid Receptor and a Regulator of Secretion.TIF by Jenna Penney (5791379)

Mutations in the QseE N-terminus impairing interaction with QseG concomitantly decrease QseE activity. by Yvonne Göpel (5549291)

Decrease in <i>D. discoideum</i> mitochondrial mRNAs during <i>L. pneumophila</i> infection. by Chenyu Zhang (107032)